EBR Systems accelerated its U.S. commercial rollout of the WiSE CRT System in Q1 2026 with implant volumes more than doubling and revenue hitting US$2.4 million. The company also secured a key regulatory milestone in Australia with TGA Priority Review, yet losses deepened and cash burn intensified, raising fresh questions about its funding runway.
- WiSE implants more than doubled to 41 in Q1 2026
- Q1 revenue reached US$2.4 million amid Limited Market Release
- TGA granted Priority Review for accelerated Australian approval
- Net loss widened to US$17.1 million with increased cash burn
- 1-for-10 reverse stock split implemented to restructure equity
Surge in WiSE Implants Drives Early Revenue
EBR Systems (ASX:EBR) delivered a notable commercial surge in the first quarter of 2026, with the number of WiSE cardiac resynchronisation therapy (CRT) system implants more than doubling quarter-on-quarter to 41 cases. This brought the total commercial implants to 71 since the pilot phase began, generating US$2.4 million (A$3.4 million) in revenue for the quarter. The company’s Limited Market Release (LMR) strategy in the U.S. is clearly gaining traction as hospital activations, physician training, and purchase agreements accelerate.
EBR trained 22 new physicians during Q1, lifting its trained physician base by nearly 70%, and signed 16 new purchase agreements, adding to the 21 secured in prior quarters. These developments underpin the company’s focus on building procedural consistency and hospital workflow to support sustainable growth. The ramp-up follows EBR’s FDA approval in April 2025 and builds on the momentum from the previous quarter’s doubling of implants and preliminary revenue guidance WiSE Implants in Q1 2026.
TGA Priority Review Accelerates Australian Prospects
Shortly after the quarter ended, EBR secured a significant regulatory boost when the Australian Therapeutic Goods Administration (TGA) granted Priority Review status to the WiSE CRT System. This designation fast-tracks the company’s application for inclusion on the Australian Register of Therapeutic Goods (ARTG), potentially enabling earlier patient access Down Under. The company plans to submit its ARTG application imminently, aiming to replicate its U.S. commercial progress in Australia, where heart failure patients face limited CRT options.
This regulatory milestone complements EBR’s FDA approval and growing U.S. commercial footprint, reinforcing the company’s global expansion ambitions TGA Priority Review for WiSE.
Financials Highlight Growing Losses and Cash Burn
Despite the encouraging commercial progress, EBR’s financial results reveal the challenges of scaling a novel medical device. The company reported a net loss of US$17.1 million for Q1 2026, a 62% increase from US$10.6 million in the same quarter last year. Operating cash outflows widened to US$20.3 million, reflecting higher personnel costs, expanded sales and marketing activities, and investments in manufacturing and clinical studies.
Gross margin stood at a modest 7.8%, buoyed by the use of previously expensed clinical trial inventory; excluding this, the margin would have been a negative 25.4%. These figures underscore the early-stage nature of the commercial rollout, with margins expected to improve organically as production scales.
Cash, cash equivalents, restricted cash, and marketable securities totaled US$30.9 million at quarter-end, down from US$54.2 million at the end of 2025. The company’s working capital remains positive at US$42.0 million, but management flagged substantial doubt about its ability to continue as a going concern beyond the next twelve months without additional capital raising. EBR is currently compliant with its debt covenants under a US$41.8 million loan facility from Runway Growth Finance Corp, due in mid-2027.
Equity Restructuring and Investor Engagement
In March, EBR implemented a 1-for-10 reverse stock split to streamline its equity structure, adjusting the CHESS Depositary Interest (CDI) conversion ratio accordingly. This move did not alter the number of CDIs held by investors but was intended to enhance trading liquidity and appeal.
Throughout Q1, EBR actively engaged with investors and the healthcare investment community, participating in major conferences including J.P. Morgan Healthcare in San Francisco and the Leerink Global Healthcare Conference in Miami. These forums provided platforms to highlight FDA approval, reimbursement progress, and early commercial traction.
Clinical and Commercial Foundations for Growth
Beyond commercial metrics, EBR continues to build clinical evidence through ongoing studies such as the WiSE-UP post-approval study and the TLC-AU feasibility study. These efforts aim to validate the safety and efficacy of the leadless WiSE CRT System, which offers a novel approach to left ventricular pacing without the complications associated with traditional leads.
The company’s strategy remains focused on targeted hospital rollouts, physician training, and reimbursement navigation to foster adoption. However, the path to broad market penetration and profitability remains uncertain, hinging on regulatory approvals, competitive dynamics, and capital availability.
Bottom Line?
EBR’s Q1 momentum and TGA Priority Review signal commercial and regulatory progress, but mounting losses and cash burn intensify the urgency for fresh capital to sustain its growth trajectory.
Questions in the middle?
- How quickly can EBR convert TGA Priority Review into ARTG approval and commercial sales in Australia?
- Will the company’s cash reserves and credit facilities suffice to reach profitability or require imminent capital raising?
- How will evolving clinical data and competitive pressures shape physician adoption of the WiSE CRT System?